Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer
NCT ID: NCT06709144
Last Updated: 2024-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
896 participants
INTERVENTIONAL
2024-07-01
2032-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group SMA
The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA).
SMA lymph node dissection
The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)
Group SMV
The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
SMV lymph node dissection
The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SMA lymph node dissection
The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)
SMV lymph node dissection
The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* T3-4 and/or N1-2M0
* Colonoscopy and pathological biopsy confirmed colon adenocarcinoma
Exclusion Criteria
* Cannot undergo curative resection
* Simultaneous multiple primary colorectal cancer or other diseases requiring segmental resection
* Distant metastasis
* Tumor invades surrounding organs, requiring joint organ resection
* Emergency surgery is required for complications such as intestinal obstruction, perforation, and bleeding
* Patients who have received neoadjuvant therapy before surgery
* Pregnant or lactating women
* Patients who are not suitable or unable to tolerate surgery
18 Years
78 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangxi Provincial Cancer Hospital
OTHER
Jiangsu Cancer Institute & Hospital
OTHER
Liaoning Cancer Hospital & Institute
OTHER
The First Affiliated Hospital of Soochow University
OTHER
Shanxi Province Cancer Hospital
OTHER
The First Affiliated Hospital of Shanxi Medical University
OTHER
Shaoxing People's Hospital
OTHER
Shaoxing Second Hospital
OTHER
Ningbo No. 1 Hospital
OTHER
Ningbo No.2 Hospital
OTHER
Jinhua Central Hospital
OTHER
Affiliated Hospital of Jiaxing University
OTHER
The First People's Hospital of Huzhou
OTHER
The Central Hospital of Lishui City
OTHER
Lishui Country People's Hospital
OTHER
Zhejiang University
OTHER
Yuyao People's Hospital
OTHER
The Third Affiliated Hospital of Wenzhou Medical University
OTHER
First Affiliated Hospital of Wenzhou Medical University
OTHER
Cancer Hospital of Guangxi Medical University
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Ruijin Hospital
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
First Affiliated Hospital of Zhejiang University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Shanghai Cancer Hospital, China
OTHER
The Affiliated Tumor Hospital of Harbin Medical University
UNKNOWN
Shanghai 10th People's Hospital
OTHER
The Second Affiliated Hospital of Harbin Medical University
OTHER
Xiangshan No.1 People' s Hospital
UNKNOWN
Zhejiang Province People's Hospital
UNKNOWN
Sir Run Run Shaw Hospital
OTHER
Sun Yat-sen University Cancer Hosptial
UNKNOWN
Haixing Ju, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haixing Ju, MD
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haixing Ju
Role: PRINCIPAL_INVESTIGATOR
Zhejiang Cancer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhejiang cancer hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024IITZA001
Identifier Type: OTHER
Identifier Source: secondary_id
IRB-2024-935（IIT）
Identifier Type: -
Identifier Source: org_study_id